Form 4 for GILD Gilead Sciences
Accepted 2026-05-18 17:45:39 ET · period of report 2026-05-15 · accession 0001782135-26-000016 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-05-18 17:45 | 2026-05-15 | GILD | Mercier Johanna | Chief Comm, Corp Aff Off | M - OptEx | $66.64 | +25.0K | 153.8K | +19% | +$1.67M |
| DMT | 2026-05-18 17:45 | 2026-05-15 | GILD | Mercier Johanna | Chief Comm, Corp Aff Off | S - Sale+OE | $131.29 | -28.0K | 125.8K | -18% | -$3.68M |
| DT | 2026-05-18 17:45 | 2026-05-15 | GILD | Mercier Johanna | Chief Comm, Corp Aff Off | M - OptEx | $0.00 | -25.0K | 23.1K | -52% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-15 | M | A | 25,000 | $66.64 | 153,779 | D | — | — | (F1) The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. |
| 2 | Common | Common Stock | 2026-05-15 | S | D | 7,749 | $130.29 | 146,030 | D | — | — | (F1) The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. (F2) Sale prices for the transactions reported range from $129.66 to $130.63. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. |
| 3 | Common | Common Stock | 2026-05-15 | S | D | 11,177 | $131.19 | 134,853 | D | — | — | (F1) The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. (F3) Sale prices for the transactions reported range from $130.67 to $131.505. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. |
| 4 | Common | Common Stock | 2026-05-15 | S | D | 8,374 | $132.23 | 126,479 | D | — | — | (F1) The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. (F4) Sale prices for the transactions reported range from $131.71 to $132.55. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. |
| 5 | Common | Common Stock | 2026-05-15 | S | D | 700 | $132.75 | 125,779 | D | — | — | (F1) The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. (F5) Sale prices for the transactions reported range from $132.74 to $132.78. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. |
| 6 | Derivative | Non-qualified Stock Option (Right to Buy) | 2026-05-15 | M | D | 25,000 | $0.00 | 23,110 | D | $66.64 · — to 2029-07-24 | 25,000 Common Stock | (F1) The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. (F6) The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |